Descriptive characteristics for patients with MF
| Variable . | HCT (n = 551) . | Non-HCT (n = 1377) . |
|---|---|---|
| Primary MF, % | 84 | 65 |
| Secondary MF, % | 16 | 35 |
| Age at diagnosis, median (range), y | 51 (20-69) | 59 (20-75) |
| Median age at HCT/referral, y | 55 | 61 |
| DIPSS at HCT/referral, % | ||
| Low | 15 | 12 |
| Int-1 | 45 | 39 |
| Int-2/high | 34 | 28 |
| Missing | 6 | 21 |
| Cytogenetics, % | ||
| Normal/favorable | 52 | 73 |
| Unfavorable | 14 | 16 |
| Missing | 34 | 11 |
| Origin, % | ||
| White | 91 | 75 |
| African American | 4 | 6 |
| Asian | 3 | 2 |
| Other | 3 | 16 |
| JAK2V617F mutation, % | ||
| Positive | 21 | 55 |
| Negative | 15 | 32 |
| Not tested or unavailable | 64 | 14 |
| Prior therapy, % | ||
| Ruxolitinib | 10 | 30 |
| Hydroxyurea | 26 | 42 |
| Immunomodulatory | 14 | 26 |
| Splenic irradiation | 2 | 3 |
| Number of prior therapies, % | ||
| 0 | 28 | 16 |
| 1 | 36 | 25 |
| 2 | 17 | 24 |
| ≥3 | 17 | 34 |
| Conditioning intensity, % | ||
| MAC | 51 | — |
| RIC | 41 | — |
| NMA | 7 | — |
| Missing | 2 | — |
| Donor type | ||
| HLA identical | 38 | — |
| Well-matched unrelated | 47 | — |
| Partially matched unrelated | 15 | — |
| Median follow up time of survivors, mo | 72 | 63 |
| Time of diagnosis to treatment, mo | 19 | 2 |
| Number of centers | 138 | 14 |
| Variable . | HCT (n = 551) . | Non-HCT (n = 1377) . |
|---|---|---|
| Primary MF, % | 84 | 65 |
| Secondary MF, % | 16 | 35 |
| Age at diagnosis, median (range), y | 51 (20-69) | 59 (20-75) |
| Median age at HCT/referral, y | 55 | 61 |
| DIPSS at HCT/referral, % | ||
| Low | 15 | 12 |
| Int-1 | 45 | 39 |
| Int-2/high | 34 | 28 |
| Missing | 6 | 21 |
| Cytogenetics, % | ||
| Normal/favorable | 52 | 73 |
| Unfavorable | 14 | 16 |
| Missing | 34 | 11 |
| Origin, % | ||
| White | 91 | 75 |
| African American | 4 | 6 |
| Asian | 3 | 2 |
| Other | 3 | 16 |
| JAK2V617F mutation, % | ||
| Positive | 21 | 55 |
| Negative | 15 | 32 |
| Not tested or unavailable | 64 | 14 |
| Prior therapy, % | ||
| Ruxolitinib | 10 | 30 |
| Hydroxyurea | 26 | 42 |
| Immunomodulatory | 14 | 26 |
| Splenic irradiation | 2 | 3 |
| Number of prior therapies, % | ||
| 0 | 28 | 16 |
| 1 | 36 | 25 |
| 2 | 17 | 24 |
| ≥3 | 17 | 34 |
| Conditioning intensity, % | ||
| MAC | 51 | — |
| RIC | 41 | — |
| NMA | 7 | — |
| Missing | 2 | — |
| Donor type | ||
| HLA identical | 38 | — |
| Well-matched unrelated | 47 | — |
| Partially matched unrelated | 15 | — |
| Median follow up time of survivors, mo | 72 | 63 |
| Time of diagnosis to treatment, mo | 19 | 2 |
| Number of centers | 138 | 14 |
Unless otherwise indicated, the data are presented as percentage of patients.
MAC, myeloablative conditioning; NMA, nonmyeloablative; RIC, reduced intensity conditioning.